DNA adduct formation by the anticancer drug ellipticine in human leukemia HL-60 and CCRF-CEM cells
Language English Country Ireland Media print-electronic
Document type Journal Article, Research Support, Non-U.S. Gov't
PubMed
17306925
DOI
10.1016/j.canlet.2006.12.037
PII: S0304-3835(07)00004-3
Knihovny.cz E-resources
- MeSH
- DNA Adducts biosynthesis MeSH
- Ellipticines pharmacology MeSH
- Leukemia pathology MeSH
- Humans MeSH
- Cell Line, Tumor MeSH
- Antineoplastic Agents pharmacology MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- DNA Adducts MeSH
- Ellipticines MeSH
- ellipticine MeSH Browser
- Antineoplastic Agents MeSH
Ellipticine induces formation of two DNA adducts in leukemia HL-60 and CCRF-CEM cells, identical with deoxyguanosine adducts generated by ellipticine metabolites 13-hydroxyellipticine and 12-hydroxyellipticine in vitro and in vivo. The ellipticine cytotoxicity to HL-60 (IC(50)=0.64microM) and CCRF-CEM cells (IC(50)=4.7microM) correlates with levels of DNA adducts. The different expressions of enzymes activating ellipticine in cells explain this finding. While cytochrome P450 1A1 and cyclooxygenase-1 are expressed in both cells, HL-60 cells express also high levels of another activator, myeloperoxidase. The results suggest the adduct formation as a new mode of antitumor action of ellipticine for leukemia.
References provided by Crossref.org
Formation of DNA adducts by ellipticine and its micellar form in rats - a comparative study
Ellipticine cytotoxicity to cancer cell lines - a comparative study